Novel experimental and early investigational drugs for the treatment of bipolar disorder

References

• Carta MG, Angst J. Screening for bipolar disorders: a public health issue. J Affect Disord. 2016;205:139–143.
   PubMed Web of Science ®Google Scholar
• Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47(4):321–332.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Kardash L, Novello S, et al., Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective. Expert Opin Drug Discov. 13(3): 221–228. 2018.
   PubMed Web of Science ®Google Scholar
• Sagar R, Pattanayak RD. Potential biomarkers for bipolar disorder: where do we stand? Indian J Med Res. 2017;145(1):7–16.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Nardi AE, De Berardis D, et al. Experimental drugs for bipolar psychosis. Expert Opin Investig Drugs. 2016;25(12):1371–1375.
   PubMed Web of Science ®Google Scholar
• Logan RW, McClung CA. Animal models of bipolar mania: the past, present, and future. Neuroscience. 2016;321:163–188.
   PubMed Web of Science ®Google Scholar
• Vieta E, Berk M, Schulze T, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Carvalho AF, Fusco A, et al. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. J Affect Disord. 2020;276:970–983.
   PubMed Web of Science ®Google Scholar
• Harrison PJ, Geddes JR, Tunbridge EM. The Emerging Neurobiology of Bipolar Disorder. Trends Neurosci. 2018;41(1):18–30.
   PubMed Web of Science ®Google Scholar
• Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38–50.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709.
   PubMed Web of Science ®Google Scholar
• Koola MM. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia. Asian J Psychiatr. 2019;40:100–102.
   PubMed Web of Science ®Google Scholar
• Kim IB, Park SC. Neural Circuitry-Neurogenesis Coupling Model of Depression. Int J Mol Sci. 2021;22(5):2468.
   PubMed Web of Science ®Google Scholar
• Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10(1):59–76.
   PubMed Web of Science ®Google Scholar
• Nery FG, Li W, and DelBello MP, et al. N-acetylcysteine as an adjunctive treatment for bipolar depression: a systematic review and meta-analysis of randomized controlled trials [published online ahead of print, 2020 Dec 22]. Bipolar Disord. 2020:1–8 .
   Web of Science ®Google Scholar
• Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012;17:1272–1282.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Tóth F, Polyák H, et al. Immune Influencers in Action: metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines. 2021;9(7):734.
   PubMed Web of Science ®Google Scholar
• Solmi M, Suresh Sharma M, Osimo EF, et al. Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: a meta-analysis of mean differences and variability. Brain Behav Immun. 2021;97:193–203.
   PubMed Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
   PubMed Web of Science ®Google Scholar
• Aftab A, Kemp DE, Ganocy SJ, et al. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. J Affect Disord. 2019;245:957–964.
   PubMed Web of Science ®Google Scholar
• Forester BP, Zuo CS, Ravichandran C, et al. Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol. 2012;25:43–50.
   PubMed Web of Science ®Google Scholar
• Piscianz E, Tesser A, Rimondi E, et al. MitoQ Is Able to Modulate Apoptosis and Inflammation. Int J Mol Sci. 2021;22(9):4753.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Huryk KM, Mao X, et al. A pilot study of minocycline for the treatment of bipolar depression: effects on cortical glutathione and oxidative stress in vivo. J Affect Disord. 2018;230:56–64.
   PubMed Web of Science ®Google Scholar
• Plane JM, Shen Y, Pleasure DE, et al. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442–1448.
   PubMedGoogle Scholar
• Tanaka M, Vécsei L. Monitoring the Redox Status in Multiple Sclerosis. Biomedicines. 2020;8(10):406.
   Web of Science ®Google Scholar
• de Melo LGP, Nunes SOV, Anderson G, et al. Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2017;78:34–50.
   PubMed Web of Science ®Google Scholar
• Soczynska JK, Kennedy SH, Alsuwaidan M, et al. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord. 2017;19:198–213.
   PubMed Web of Science ®Google Scholar
• Cohen IV, Makunts T, Atayee R, et al. Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Sci Rep. 2017;7:1450.
   PubMed Web of Science ®Google Scholar
• Zheng LS, Kaneko N, Sawamoto K. Minocycline treatment ameliorates interferon-alpha-induced neurogenic defects and depression-like behaviors in mice. Front Cell Neurosci. 2015;9:5.
   PubMed Web of Science ®Google Scholar
• Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and −2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci. 2009;30:174–181.
   PubMed Web of Science ®Google Scholar
• Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87–94.
   PubMed Web of Science ®Google Scholar
• Catanesi M, d’Angelo M, Tupone MG, et al. MicroRNAs Dysregulation and Mitochondrial Dysfunction in Neurodegenerative Diseases. Int J Mol Sci. 2020;21(17):5986.
   Web of Science ®Google Scholar
• Sleigh J, Harvey M, Voss L, et al. Ketamine-More mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76e8.
   Google Scholar
• Carlson PJ, Diazgranados N, Nugent AC, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013;73(12):1213–1221.
   PubMed Web of Science ®Google Scholar
• Ballard ED, Lally N, Nugent AC, et al. Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol. 2014;18(1): pyu069.
   Web of Science ®Google Scholar
• Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607.
   PubMed Web of Science ®Google Scholar
• Miller J. Ketamine/esketamine: putative mechanisms of action. Curr Psychiatry. 2020;19(1):32–36.
   Google Scholar
• Fornaro M, De Berardis D, Anastasia A, et al. Novel Psychopharmacology for Depressive Disorders. Adv Exp Med Biol. 2021;1305:449–461.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Spravato label. Updated February 2020.
   Google Scholar
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.Am. J Geriatr Psychiatry. 2020;28:121–141.
   Google Scholar
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22:616–630.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: a Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893–903.
   PubMed Web of Science ®Google Scholar
• Zhan Z, Wang X, Chen Q, et al. Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis. BMJ Open. 2021;11(2):e043457.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor [published online ahead of print, 2021 May 7]. Mol Psychiatry. 2021. doi:https://doi.org/10.1038/s41380-021-01121-1
   Google Scholar
• Shirayama Y, Hashimoto K. Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci. 2017;267:177–182.
   PubMed Web of Science ®Google Scholar
• Palacios J, Yildiz A, Young AH, et al. Tamoxifen for bipolar disorder: systematic review and meta-analysis. J Psychopharmacol. 2019;33(2):177–184.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65:255–263.
   PubMed Web of Science ®Google Scholar
• Serra G, Demontis F, Serra F, et al. Memantine: new prospective in bipolar disorder treatment. World J Psychiatry. 2014;4(4):80–90.
   PubMedGoogle Scholar
• Marx CE, Shampine LJ, Duncan GE, et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav. 2006;84(4):598–608.
   PubMed Web of Science ®Google Scholar
• Bessa JM, Ferreira D, Melo I, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry. 2009;14(8):764–773.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Maritan E, Ferranti R, et al. Lithium Exposure During Pregnancy and the Postpartum Period: a Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. Am J Psychiatry. 2020;177(1):76–92.
   PubMed Web of Science ®Google Scholar
• Miller MN, Miller BE. Premenstrual exacerbations of mood disorders. Psychopharmacol Bull. 2001;35(3):135–149.
   PubMedGoogle Scholar
• Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct. 2012;8:61.
   PubMed Web of Science ®Google Scholar
• Masaki C, Sharpley AL, Godlewska BR, et al. Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla. Psychopharmacology (Berl). 2016;233:1097–1104.
   PubMed Web of Science ®Google Scholar
• Kordestani-Moghadam P, Nasehi M, Khodagholi F, et al. The fluctuations of metabotropic glutamate receptor subtype 5 (mGluR5) in the amygdala in fear conditioning model of male Wistar rats following sleep deprivation, reverse circadian and napping. Brain Res. 2020;1734:146739.
   PubMed Web of Science ®Google Scholar
• Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002;63(2):146–151.
   PubMed Web of Science ®Google Scholar
• Muneer A. The Neurobiology of Bipolar Disorder: an Integrated Approach. Chonnam Med J. 2016;52(1):18–37.
   PubMedGoogle Scholar
• Carvalho AF, Solmi M, Sanches M, et al. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Transl Psychiatry. 2020;10(1):152.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Anastasia A, et al. The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: a plea for further research attention. Psychiatry Res. 2018;269:658–672.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Montemitro C, Pettorruso M, et al. Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability. Expert Opin Pharmacother. 2019;20(13):1575–1588.
   PubMed Web of Science ®Google Scholar
• Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–529.
   PubMed Web of Science ®Google Scholar
• Stertz L, Magalhães PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry. 2013;26(1):19–26.
   PubMed Web of Science ®Google Scholar
• Eaton WW, Pedersen MG, Nielsen PR, et al. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638–646.
   PubMed Web of Science ®Google Scholar
• Perugi G, Quaranta G, Belletti S, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord. 2015;170:95–103.
   PubMed Web of Science ®Google Scholar
• Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2010;15(3):453–466.
   PubMed Web of Science ®Google Scholar
• Hoertel N, De Maricourt P, Gorwood P. Novel routes to bipolar disorder drug discovery. Expert Opin Drug Discov. 2013;8(8):907–918.
   PubMed Web of Science ®Google Scholar
• Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395–397.
   PubMed Web of Science ®Google Scholar
• Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Daban C, et al., Clinical and therapeutic implications of predominant polarity in bipolar disorder. Affect Disord. 93(1–3): 13–17. 2006.
   PubMed Web of Science ®Google Scholar
• Latalova K, Prasko J, Grambal A, et al. Bipolar disorder and anxiety disorders. Neuro Endocrinol Lett. 2013;34(8):738–744.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Koshy AS, et al. Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat. 2016;12:719–735.
   PubMed Web of Science ®Google Scholar
• Stahl S. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123–127.
   PubMed Web of Science ®Google Scholar
• Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Braz J Psychiatry. 2006;28(3):252–254.
   PubMedGoogle Scholar